Rosetta Aims to Launch New microRNA Test Annually Starting Next Year | GenomeWeb

Rosetta Genomics this week announced updates to its pipeline of microRNA-based diagnostics and therapeutics, stating that it will start commercializing one new assay a year as it moves a treatment for cytomegalovirus (CMV) infection toward the clinic.

Notably, some of these diagnostics will be for indications outside of cancer, which has been the company's main area of interest.

Rosetta was founded in 2000 to develop both miRNA diagnostics and therapeutics, but later shifted its focus to diagnostics, primarily for cancer indications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.